Why BioNTech SE’s (BNTX) Stock Is Up 18.49%
As of Wednesday, August 19, BioNTech SE’s BNTX share price has surged by 18.49%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Commentary & Analysis
Why BioNTech SE’s (BNTX) Stock Is Up 19.85%
As of Wednesday, August 19, BioNTech SE’s BNTX share price has surged by 19.85%, which has investors questioning if this is right time to sell.Omar Beirat
Which Is a Better Investment, BioNTech SE or BeOne Medicines AG Stock?
Learn more about whether BioNTech SE or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, BioNTech SE or Halozyme Therapeutics, Inc. Stock?
Learn more about whether BioNTech SE or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
What You Need to Know About BioNTech SE's Q3 Earnings
BioNTech SE's fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (BNTX) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $27,856.1 | $286.3 | 89% |
|
| Shares Out (Mil) | 289.4 | 54.2 | 82% |
|
| Institutional Ownership | 55.9% | 92.8% | 38% |
|
| Float (Mil) | 108.4 | 39.7 | 63% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,864 | 534 | 81% |
|
| Price Change (52-week) |
(0.5%) | 58.7% | 44% |
|
| Growth | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 41.7% | 13.6% | 94% |
|
| Net Income (5yr) | (136.3%) | (10.1%) | 1% |
|
| EPS (5yr) | (138.8%) | 16.0% | 0 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (37.7%) | (15.6%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 9 | 9 | |
| Current EPS | $0.884 | ($5.800) | ($5.678) | |
| Month Ago EPS | $0.767 | ($4.978) | ($5.055) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.426 | ($5.372) | ($5.248) | |
| Year/Year Chg | (123.9%) | 5.1% | (24.0%) | |
| Financials | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,028 | $37 | 66% |
|
| Net Income (TTM) (Mil) | ($1,927) | ($43) | 1% |
|
| EPS (TTM) | ($7.773) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | $777 | ($31) | 77% |
|
| Net Cash Flow (TTM) (Mil) | ($693) | $2 | 5% |
|
| Long-Term Debt (Q1) (Mil) | $296 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | na | $160 | na |
|
| Valuation | BNTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.37 | 2.77 | 35% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.6% | 64.2% | 86% |
|
| Net Margin | (63.6%) | (75.9%) | 10% |
|
| ROA | (7.9%) | (47.3%) | 27% |
|
| ROE | (9.2%) | (55.0%) | 28% |
|
| Liabilities to Assets | 12.7% | 29.6% | 8% |
|
| F-Score | 2 | 2 | 7% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.9% |
| +/- S&P 500: | -4.6 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
